Targeting Hsp90 in CRC is of particular interest due to high incidence of KRAS mutations and constitutive activation of Ras/Raf/MEK/Erk signaling, pathways susceptible to Hsp90 inhibition. The gene discussed is MAP2K7; the disease is colorectal carcinoma.